Update for Surgeons: Recent and Noteworthy Changes in Therapeutic Regimens for Cancer of the Colon and Rectum

Journal of the American College of Surgeons

Volumn 205, Issue 3, 2007, Pages

  Hriesik, Claudia ^a   Ramanathan, Ramesh K ^a   Hughes, Steven J ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LEVAMISOLE; OXALIPLATIN; PANITUMUMAB;

ANTINEOPLASTIC ACTIVITY; BLEEDING; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER REGRESSION; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL PRACTICE; CLINICAL TRIAL; COLON CANCER; COMBINATION CHEMOTHERAPY; CONJUNCTIVITIS; DERMATITIS; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; FATIGUE; HAND FOOT SYNDROME; HEARING LOSS; HUMAN; HYPERTENSION; INFECTION; INTERSTITIAL LUNG DISEASE; INTESTINE PERFORATION; LEUKOPENIA; MONOTHERAPY; MUCOSA INFLAMMATION; NAUSEA; NAUSEA AND VOMITING; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PALLIATIVE THERAPY; PRIORITY JOURNAL; PROTEINURIA; RASH; RECTUM CANCER; REVIEW; SENSORY NEUROPATHY; STOMATITIS; SURGEON; TONGUE SWELLING; TREATMENT OUTCOME; TREATMENT PLANNING; VEIN THROMBOSIS; WOUND HEALING IMPAIRMENT;

EID: 34548179401     PISSN: 10727515     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jamcollsurg.2007.04.032     Document Type: Review

References (86)

1. Greenlee R.T., Murray T., Bolden S., and Wingo P.A. Cancer statistics, 2000. CA Cancer J Clin 50 (2000) 7-33
2. Moertel C.G., Fleming T.R., Macdonald J.S., et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322 (1990) 352-358
3. Moertel C.G. Accomplishments in surgical adjuvant therapy for large-bowel cancer. Cancer 70 (1992) 1364-1371
4. Saltz L.B., Cox J.V., Blanke C., et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343 (2000) 905-914
5. Douillard J.Y., Cunningham D., Roth A.D., et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355 (2000) 1041-1047
6. de Gramont A., Tournigand C., Louvet C., et al. First-line therapy for advanced colorectal cancer. Curr Oncol Rep 7 (2005) 167-172
7. Goldberg R.M., Sargent D.J., Morton R.F., et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22 (2004) 23-30
8. Green E., Sargent D., Goldberg R., et al. Detailed analysis of oxaliplatin-associated neurotoxicity in Intergroup trial N9741. Program and abstracts of the American Society of Clinical Oncology (2005)
9. Andre T., Boni C., Mounedji-Boudiaf L., et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350 (2004) 2343-2351
10. Andre T., Sargent D., Tabernero J., et al. Current issues in adjuvant treatment of stage II colon cancer. Ann Surg Oncol 13 (2006) 887-898
11. Van Cutsem E., Labianca R., Hossfeld D., et al. Randomized phase III trial comparing infused irinotecan/5-fluorouracil (5-FU)/folinic acid (IF) versus 5-FU/FA (F) in stage III colon cancer patients (Pts). (PETACC3). Proc Am Soc Clin Oncol 23 (2005)
12. Van Cutsem E., Labianca R., Hossfeld D., et al. Pan European Trial of Adjuvant Colon Cancer (PETACC) 3. ASCO Annual Meeting Proc 23 (2005)
13. Ychou M., Raoul J.-L., Douillard R., et al. A phase III randomized trial of LV5FU2+CPT-11 vs. LV5FU2 alone in adjuvant high risk colon cancer (FNCLCC Accord02/FFCD9802). Program and abstracts of the American Society of Clinical Oncology (2005) Annual Meeting.
14. Saltz L.B., Niedzwiecki D., Hollis D., et al. Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage III colon cancer (intergroup trial CALGB C89803). Program and abstracts of the American Society of Clinical Oncology (2004)
15. Hurwitz H.I. New agents in colon cancer. Clin Adv Hematol Oncol 1 (2003) 404-405
16. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342
17. Giantonio B.J., Levy D.E., O'Dwyer P.J., et al. A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200. Ann Oncol 17 (2006) 1399-1403
18. Hochster H.S., Welles L., Hart L., et al. Bevacizumab with oxaliplatin-based chemotherapy in the first-line therapy of metastatic colorectal cancer: preliminary results of the randomized TREE-2 trial. Program and abstracts of the American Society of Clinical Oncology (2005) Gastrointestinal Cancers Symposium.
19. Hochster H.S. Bevacizumab in combination with chemotherapy: first-line treatment of patients with metastatic colorectal cancer. Semin Oncol 33 (2006) S8-S14
20. Twelves C., Wong A., Nowacki M.P., et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 352 (2005) 2696-2704
21. Haller D., Cassidy J., Clarke S., et al. Tolerability of fluoropyrimidines appears to differ by region. ASCO Annual Meeting Proc 24 18S (2006)
22. Cunningham D., Humblet Y., Siena S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351 (2004) 337-345
23. Saltz L.B., Meropol N.J., Loehrer Sr. P.J., et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22 (2004) 1201-1208
24. Saltz L.B. Can the addition of cetuximab to irinotecan improve outcome in colorectal cancer?. Nat Clin Pract Oncol 2 (2005) 20-21
25. Saltz L.B., Lenz H., Kindler H.L., et al. Interim report of randomized phase II trial of cetuximab/bevacizumab/irinotecan versus cetuximab/bevacizumab in irinotecan-refractory colorectal cancer. Program and abstracts of the American Society of Clinical Oncology (2005) Gastrointestinal Cancers Symposium.
26. Chua Y.J., and Cunningham D. Panitumumab. Drugs Today (Barc) 42 (2006) 711-719
27. Goldberg R.M., Rothenberg M.L., Van Cutsem E., et al. The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist 12 (2007) 38-50
28. Prolongation of the disease-free interval in surgically treated rectal carcinoma. Gastrointestinal Tumor Study Group. N Engl J Med 312 (1985) 1465-1472
29. Krook J.E., Moertel C.G., Gunderson L.L., et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 324 (1991) 709-715
30. Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish Rectal Cancer Trial. N Engl J Med 336 (1997) 980-987
31. Birgisson H., Pahlman L., Gunnarsson U., and Glimelius B. Adverse effects of preoperative radiation therapy for rectal cancer: long-term follow-up of the Swedish Rectal Cancer Trial. J Clin Oncol 23 (2005) 8697-8705
32. Kapiteijn E., Marijnen C.A., Nagtegaal I.D., et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 345 (2001) 638-646
33. Stryker S.J., Kiel K.D., Rademaker A., et al. Preoperative "chemoradiation" for stages II and III rectal carcinoma. Arch Surg 131 (1996) 514-518
34. Chari R.S., Tyler D.S., Anscher M.S., et al. Preoperative radiation and chemotherapy in the treatment of adenocarcinoma of the rectum. Ann Surg 221 (1995) 778-786
35. Abdalla E.K., Adam R., Bilchik A.J., et al. Improving resectability of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol 13 (2006) 1271-1280
36. Jaeck D., Bachellier P., Guiguet M., et al. Long-term survival following resection of colorectal hepatic metastases. Association Francaise de Chirurgie. Br J Surg 84 (1997) 977-980
37. Poston G., Adam R., and Vauthey J.N. Downstaging or downsizing: time for a new staging system in advanced colorectal cancer?. J Clin Oncol 24 (2006) 2702-2706
38. Ho W.M., Ma B., Mok T., et al. Liver resection after irinotecan, 5-fluorouracil, and folinic acid for patients with unresectable colorectal liver metastases: a multicenter phase II study by the Cancer Therapeutic Research Group. Med Oncol 22 (2005) 303-312
39. Tournigand C., Andre T., Achille E., et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22 (2004) 229-237
40. Tanaka K., Adam R., Shimada H., et al. Role of neoadjuvant chemotherapy in the treatment of multiple colorectal metastases to the liver. Br J Surg 90 (2003) 963-969
41. Adam R., Pascal G., Castaing D., et al. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases?. Ann Surg 240 (2004) 1052-1061
42. Adam R., Delvart V., Pascal G., et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 240 (2004) 644-657
43. Adam R. Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases. Ann Oncol 14 suppl 2 (2003) ii13-ii16
44. Kornprat P., Jarnagin W.R., Gonen M., et al. Outcome after hepatectomy for multiple (four or more) colorectal metastases in the era of effective chemotherapy. Ann Surg Oncol 14 (2007) 1151-1160
45. Ellis L.M., Curley S.A., and Grothey A. Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab. J Clin Oncol 23 (2005) 4853-4855
46. Scappaticci F.A., Fehrenbacher L., Cartwright T., et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 91 (2005) 173-180
47. Assy N., Spira G., Paizi M., et al. Effect of vascular endothelial growth factor on hepatic regenerative activity following partial hepatectomy in rats. J Hepatol 30 (1999) 911-915
48. Kraizer Y., Mawasi N., Seagal J., et al. Vascular endothelial growth factor and angiopoietin in liver regeneration. Biochem Biophys Res Commun 287 (2001) 209-215
49. Gordon M.S., Margolin K., Talpaz M., et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19 (2001) 843-850
50. Benson III A.B., Schrag D., Somerfield M.R., et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 22 (2004) 3408-3419
51. Wong J.H., Severino R., Honnebier M.B., et al. Number of nodes examined and staging accuracy in colorectal carcinoma. J Clin Oncol 17 (1999) 2896-2900
52. Prandi M., Lionetto R., Bini A., et al. Prognostic evaluation of stage B colon cancer patients is improved by an adequate lymphadenectomy: results of a secondary analysis of a large scale adjuvant trial. Ann Surg 235 (2002) 458-463
53. Le Voyer T.E., Sigurdson E.R., Hanlon A.L., et al. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. J Clin Oncol 21 (2003) 2912-2919
54. Chen S.L., and Bilchik A.J. More extensive nodal dissection improves survival for stages I to III of colon cancer: a population-based study. Ann Surg 244 (2006) 602-610
55. Comparison of flourouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial. QUASAR Collaborative Group. Lancet 355 (2000) 1588-1596
56. Xi L., Gooding W., McCarty K., et al. Identification of mRNA markers for molecular staging of lymph nodes in colorectal cancer. Clin Chem 52 (2006) 520-523
57. Adell G., Boeryd B., Franlund B., et al. Occurrence and prognostic importance of micrometastases in regional lymph nodes in Dukes' B colorectal carcinoma: an immunohistochemical study. Eur J Surg 162 (1996) 637-642
58. Greenson J.K., Isenhart C.E., Rice R., et al. Identification of occult micrometastases in pericolic lymph nodes of Duke's B colorectal cancer patients using monoclonal antibodies against cytokeratin and CC49. Correlation with long-term survival. Cancer 73 (1994) 563-569
59. Kronberg U., Lopez-Kostner F., Soto G., et al. Detection of lymphatic micrometastases in patients with stages I and II colorectal cancer: impact on five-year survival. Dis Colon Rectum 47 (2004) 1151-1157
60. Cutait R., Alves V.A., Lopes L.C., et al. Restaging of colorectal cancer based on the identification of lymph node micrometastases through immunoperoxidase staining of CEA and cytokeratins. Dis Colon Rectum 34 (1991) 917-920
61. Broll R., Schauer V., Schimmelpenning H., et al. Prognostic relevance of occult tumor cells in lymph nodes of colorectal carcinomas: an immunohistochemical study. Dis Colon Rectum 40 (1997) 1465-1471
62. Oberg A., Stenling R., Tavelin B., and Lindmark G. Are lymph node micrometastases of any clinical significance in Dukes Stages A and B colorectal cancer?. Dis Colon Rectum 41 (1998) 1244-1249
63. Haboubi N.Y., Abdalla S.A., Amini S., et al. The novel combination of fat clearance and immunohistochemistry improves prediction of the outcome of patients with colorectal carcinomas: a preliminary study. Int J Colorectal Dis 13 (1998) 99-102
64. Yasuda K., Adachi Y., Shiraishi N., et al. Pattern of lymph node micrometastasis and prognosis of patients with colorectal cancer. Ann Surg Oncol 8 (2001) 300-304
65. Jeffers M.D., O'Dowd G.M., Mulcahy H., et al. The prognostic significance of immunohistochemically detected lymph node micrometastases in colorectal carcinoma. J Pathol 172 (1994) 183-187
66. Palma R.T., Waisberg J., Bromberg S.H., et al. Micrometastasis in regional lymph nodes of extirpated colorectal carcinoma: immunohistochemical study using anti-cytokeratin antibodies AE1/AE3. Colorectal Dis 5 (2003) 164-168
67. Tschmelitsch J., Klimstra D.S., and Cohen A.M. Lymph node micrometastases do not predict relapse in stage II colon cancer. Ann Surg Oncol 7 (2000) 601-608
68. Clarke G., Ryan E., O'Keane J.C., et al. The detection of cytokeratins in lymph nodes of Duke's B colorectal cancer subjects predicts a poor outcome. Eur J Gastroenterol Hepatol 12 (2000) 549-552
69. Noura S., Yamamoto H., Ohnishi T., et al. Comparative detection of lymph node micrometastases of stage II colorectal cancer by reverse transcriptase polymerase chain reaction and immunohistochemistry. J Clin Oncol 20 (2002) 4232-4241
70. Merrie A.E., van Rij A.M., Dennett E.R., et al. Prognostic significance of occult metastases in colon cancer. Dis Colon Rectum 46 (2003) 221-231
71. Liefers G.J., Cleton-Jansen A.M., van de Velde C.J., et al. Micrometastases and survival in stage II colorectal cancer. N Engl J Med 339 (1998) 223-228
72. Hayashi N., Ito I., Yanagisawa A., et al. Genetic diagnosis of lymph-node metastasis in colorectal cancer. Lancet 345 (1995) 1257-1259
73. Rosenberg R., Hoos A., Mueller J., et al. Prognostic significance of cytokeratin-20 reverse transcriptase polymerase chain reaction in lymph nodes of node-negative colorectal cancer patients. J Clin Oncol 20 (2002) 1049-1055
74. Bustin S.A., Siddiqi S., Ahmed S., et al. Quantification of cytokeratin 20, carcinoembryonic antigen and guanylyl cyclase C mRNA levels in lymph nodes may not predict treatment failure in colorectal cancer patients. Int J Cancer 108 (2004) 412-417
75. Iddings D., Ahmad A., Elashoff D., and Bilchik A. The prognostic effect of micrometastases in previously staged lymph node negative (N0) colorectal carcinoma: a meta-analysis. Ann Surg Oncol 13 (2006) 1386-1392
76. Saha S., Dan A.G., Bilchik A.J., et al. Historical review of lymphatic mapping in gastrointestinal malignancies. Ann Surg Oncol 11 (2004) 245S-249S
77. Thomas K.A., Lechner J., Shen P., et al. Use of sentinel node mapping for cancer of the colon: "to map or not to map.". Am Surg 72 (2006) 606-611
78. Schena M., Shalon D., Davis R.W., and Brown P.O. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 270 (1995) 467-470
79. Beer D.G., Kardia S.L., Huang C.C., et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 8 (2002) 816-824
80. Eschrich S., Yang I., Bloom G., et al. Molecular staging for survival prediction of colorectal cancer patients. J Clin Oncol 23 (2005) 3526-3535
81. Wang Y., Jatkoe T., Zhang Y., et al. Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J Clin Oncol 22 (2004) 1564-1571
82. Jensen E.H., McLoughlin J.M., and Yeatman T.J. Microarrays in gastrointestinal cancer: is personalized prediction of response to chemotherapy at hand?. Curr Opin Oncol 18 (2006) 374-380
83. Croner R.S., Peters A., Brueckl W.M., et al. Microarray versus conventional prediction of lymph node metastasis in colorectal carcinoma. Cancer 104 (2005) 395-404
84. Paik S., Tang G., Shak S., et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24 (2006) 3726-3734
85. Paik S., Shak S., Tang G., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351 (2004) 2817-2826
86. O'Connell M.J., Paik S., Yothers G., et al. Relationship between tumor gene expression and recurrence in stage II/III colon cancer: Quantitative RT-PCR assay of 757 genes in fixed paraffin-embedded (FPE) tissue. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I 24 (2006) (18S June 20 suppl)